Loading
Reviva Pharmaceuticals Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Patel Purav, was filed 21 Nov 2022.
Reviva Pharmaceuticals Holdings, Inc.: what insiders have been doing
This page follows insider dealings at Reviva Pharmaceuticals Holdings, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Reviva Pharmaceuticals Holdings, Inc. in twelve months, the latest record being from 21 November 2022.
The full history, which starts in 2018, counts 12 purchases against 19 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -19.9 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€13M
12 ops. · all time
Sell Volume
€6M
19 ops. · all time
Since the insiders bought
- +4.6%Entry US$86.60 · Close at T+365 US$90.60
- +166.0%Entry US$41.20 · Close at T+365 US$109.60
- -63.7%Entry US$99.20 · Close at T+365 US$36.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.45
Analyst consensus
2 analysts1.00/5
US$5.00Target US$17.50(+3789%)US$30.00
Income statement
EBITDA-US$19.8M
Net income-US$19.9M0.0% margin
Valuation
PER (forward)-0.5x
P/Book0.4x
Beta0.48
Balance sheet & cash
Market capUS$5.9M
Total debtUS$406.9k
Free Cash Flow-US$24.6M
Debt / Equity1%
Profitability & ownership
ROE-176.6%
ROA-51.4%
% insiders7.7%
% institutions8.2%
Last declaration on 21 November 2022
Declarations34 total
3,000 shares@ US$4.69100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001437749-22-027849:0
Canonical exit: 16 Feb 2023 (T+90)
50,000 shares@ US$1.6659.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001437749-22-023485:0
Canonical exit: 29 Dec 2022 (T+90)
50,000 shares@ US$1.21341.12% mcap40.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001437749-22-016306:0
Canonical exit: 28 Sept 2022 (T+90)
399,000 shares@ US$3.7530.0% of flowCommon StockSEC:0001062993-21-005353:1
Canonical exit: 30 Aug 2021 (T+90)
931,000 shares@ US$3.75100.0% of flowCommon StockSEC:0001062993-21-005353:0
Canonical exit: 30 Aug 2021 (T+90)
197,500 sharesCommon StockSEC:0001104659-20-139933:0
367,000 shares@ US$10.88Ordinary Shares, no par valueSEC:0001076809-20-000322:0
606,360 shares@ US$10.88Ordinary Shares, no par valueSEC:0001076809-20-000307:0
50,000 shares@ US$11.51Ordinary Shares, no par valueSEC:0001393825-20-000141:0
710,000 shares@ US$10.88Ordinary Shares, no par valueSEC:0001393825-20-000141:1
261 shares@ US$11.00Ordinary Shares, no par valueSEC:0001076809-20-000291:0
5,969 shares@ US$10.90Ordinary Shares, no par valueSEC:0001076809-20-000282:0
5,362 shares@ US$11.00Ordinary Shares, no par valueSEC:0001076809-20-000282:1
23,611 shares@ US$10.90Ordinary Shares, no par valueSEC:0001076809-20-000259:0
7,103 shares@ US$10.90Ordinary Shares, no par valueSEC:0001076809-20-000259:1
305 shares@ US$10.90Ordinary Shares, no par valueSEC:0001076809-20-000250:0
127 shares@ US$10.90Ordinary Shares, no par valueSEC:0001076809-20-000250:1
896 shares@ US$10.90Ordinary Shares, no par valueSEC:0001076809-20-000250:2
5 shares@ US$10.90100.0% of flowOrdinary Shares, no par valueSEC:0001076809-20-000244:0
1 shares@ US$10.90Ordinary Shares, no par valueSEC:0001076809-20-000234:0
1 shares@ US$11.50Ordinary Shares, no par valueSEC:0001076809-20-000213:0
57,616 shares@ US$10.85Ordinary Shares, no par valueSEC:0001076809-20-000213:1
10,000 shares@ US$10.37Ordinary Shares, no par valueSEC:0001393825-20-000131:0
Canonical exit: 18 Jun 2020 (T+90)
50,000 shares@ US$10.87Ordinary Shares, no par valueSEC:0001393825-20-000131:1
2 shares@ US$11.50Ordinary Shares, no par valueSEC:0001076809-20-000171:0
25 of 34 declarations
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a U.S.-based clinical-stage biopharmaceutical company headquartered in Cupertino, California, United States. For French-speaking investors, it fits the profile of a small-cap healthcare name whose equity story is driven less by current sales than by the progress of a proprietary drug pipeline, clinical data, regulatory milestones, and financing capacity. The company was originally incorporated in Delaware in 2006 and has since developed an internal chemical genomics and medicinal chemistry platform. It also reports a foreign operating subsidiary, Reviva Pharmaceuticals India Pvt. Ltd., which gives it a modest international operating footprint beyond the United States.
Reviva’s business model is centered on discovering, developing, and seeking to commercialize next-generation therapeutics for diseases with significant unmet medical need, especially in central nervous system, inflammatory, cardiometabolic, and related therapeutic areas. Its pipeline is currently anchored by two drug candidates: brilaroxazine (RP5063) and RP1208. Brilaroxazine is the lead and most strategically important asset. The company has positioned it primarily for schizophrenia and more broadly for neuropsychiatric disorders, while also describing potential applications across other CNS and inflammatory settings. RP1208 remains part of the portfolio, but the investment case is overwhelmingly dependent on the progression of brilaroxazine through late-stage development, regulatory engagement, and, eventually, a possible partnership or commercialization path.
Read moreShow less
From a competitive standpoint, Reviva is not yet a commercial-stage pharmaceutical company and does not compete on revenue scale, geographic reach, or product breadth with large-cap peers. Instead, it competes in the high-risk, high-upside category of clinical biotech, where valuation is shaped by data quality, trial design, patent protection, and the market’s perception of probability-adjusted success. That makes the stock especially sensitive to clinical readouts, FDA interactions, and capital raises.
Recent corporate developments are material. Reviva reported several equity financings in 2025 and March 2026 to support research and development, including funding for its planned RECOVER-2 Phase 3 trial in schizophrenia. Following the March 2026 financing, the company said it had approximately $23 million in cash and cash equivalents and expected to fund operations into Q1 2027. Reviva also completed a 1-for-20 reverse stock split effective March 9, 2026, a common action among micro- and small-cap biotechnology issuers seeking to maintain listing compliance and improve share-price optics. On the pipeline side, management indicated it plans to initiate RECOVER-2 in mid-2026 and continue pursuing partnerships. In addition, the European Patent Office granted a patent in November 2025 covering brilaroxazine for pulmonary fibrosis, including idiopathic pulmonary fibrosis, which strengthens the company’s intellectual-property position in key global markets. Overall, RVPH remains a speculative NASDAQ-listed U.S. biotech story with limited current commercialization but meaningful optionality if late-stage clinical execution improves.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
